Vizsgálati helyszín
Norrlands University Hospital
Umeå, Region Västerbotten 901 85, SvédországMég nincs intézményhez kötve
- 20futó vizsgálat
- 9lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 30 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis19 vizsgálat
- 2. fázis6 vizsgálat
- 1. fázis2 vizsgálat
- 4. fázis1 vizsgálat
- Állapot
- Toboroz13 vizsgálat
- Lezárult9 vizsgálat
- Még nem toboroz4 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Felfüggesztve1 vizsgálat
- Fő szponzor
- Karolinska University Hospital6 vizsgálat
- Amgen2 vizsgálat
- Gustave Roussy, Cancer Campus, Grand Paris2 vizsgálat
- Novo Nordisk A/S2 vizsgálat
- Aarhus University Hospital1 vizsgálat
- és még 17
Futó vizsgálatok
Toboroz
Fight Osteosarcoma Through European Research Evolving Study Platform From Diagnosis to Relapse
NCT07871864· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Contact: Caroline BJÖRKLUND
Toboroz
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01· 3. fázis· Institut Gustave Roussy· Forrás
Toboroz
Selenium Intervention Registry Randomized Trial in Heart Failure
NCT07543562· 3. fázis· Skane University Hospital· Forrás
Contact: Therese Andersson
Toboroz
Primary treatment of follicular lymphoma with rituximab-lenalidomide-tafasitamab for high-risk disease and rituximab-lenalidomide with a 1:1 randomization to tafasitamab for low-risk disease: a phase II study – NLG-FL7
2023-508196-36-00· 2. fázis· Karolinska University Hospital· Forrás
Toboroz
A Phase III Randomized Controlled Multicentre Trial of Percutaneous Hepatic Perfusion in Combination with Ipilimumab and Nivolumab Compared to Ipilimumab and Nivolumab Only in Patients with Uveal Melanoma Liver Metastases – the SCANDIUM III trial.
2023-508156-20-00· 3. fázis· Vaestra Goetalandsregionen· Forrás
Toboroz
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629· 3. fázis· Intellia Therapeutics· Forrás
Toboroz
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356· 3. fázis· Amgen· Forrás
Fut, nem toboroz
Phase II multicenter clinical trial: Mosunetuzumab for early relapse of follicular lymphoma in the Nordic countries (MERLIN/NLG-FL6/ML43841)
2022-500100-21-01· 2. fázis· Oslo University Hospital Hf· Forrás
Toboroz
NOAC9 - Circulating Tumor DNA Guided Follow-Up in Anal Cancer
NCT05572801· Aarhus University Hospital· Forrás
Contact: Birgitta Lindh
Toboroz
A Randomized Trial of Trastuzumab Deruxtecan and Biology-Driven Selection of Neoadjuvant Treatment for HER2-positive Breast Cancer
NCT05900206· 2. fázis· Karolinska University Hospital· Forrás
Toboroz
SACK
2022-501600-10-00· 3. fázis· Karolinska University Hospital· Forrás
Toboroz
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
NCT05327894· 3. fázis· Princess Maxima Center for Pediatric Oncology· Forrás
Toboroz
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
NCT05377047· 3. fázis· Vastra Gotaland Region· Forrás
Contact: Dmitry Domkin, Study nurse
Toboroz
NMDSG-14B2
2024-511651-17-00· 2. fázis· Karolinska University Hospital· Forrás
Toboroz
A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma
NCT04332822· 3. fázis· Nordic Lymphoma Group· Forrás
Toboroz
Randomised Evaluation of COVID-19 Therapy
NCT04381936· 3. fázis· University of Oxford· Forrás
Toboroz
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
NCT04221035· 3. fázis· Gustave Roussy, Cancer Campus, Grand Paris· Forrás
Toboroz
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
NCT03968393· 4. fázis· Population Health Research Institute· Forrás
Toboroz
Comparing "Salvage" Radiotherapy and Individualized PSMA PET/CT Targeted Treatment in With Relapsing Prostate Cancer
NCT04794777· 3. fázis· Stefan Carlsson· Forrás
Fut, nem toboroz
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT02960022· 2. fázis· Astellas Pharma Global Development, Inc.· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)
NCT06453668· 1. fázis· Itb-Med AB· Forrás
Lezárult
BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to conventional staging in women with presumed early-stage endometrial cancer.
2023-505991-31-00· 3. fázis· Karolinska University Hospital· Forrás
Lezárult
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)
NCT05349721· 2. fázis· PTC Therapeutics Inc.· Forrás
Lezárult
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT05052801· 3. fázis· Amgen· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)
NCT04777396· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
NCT04777409· 3. fázis· Novo Nordisk A/S· Forrás
Lezárult
AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC
NCT04006405· Elypta· Forrás
Lezárult
Intermittent ibrutinib in chronic lymphocytic leukemia
2023-508638-32-00· 1. fázis· Karolinska University Hospital· Forrás
Lezárult
A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma
NCT03277105· 3. fázis· Janssen Research & Development, LLC· Forrás
Hibát jelzek